Interpace Biosciences, Inc. (OTCMKTS:IDXG) Short Interest Down 61.0% in June

Interpace Biosciences, Inc. (OTCMKTS:IDXG) was the recipient of a large drop in short interest in the month of June. As of June 30th, there was short interest totaling 306 shares, a drop of 61.0% from the June 15th total of 785 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 14,473 shares, the short-interest ratio is presently 0.0 days.

Interpace Biosciences Stock Performance

IDXG opened at $1.64 on Monday. Interpace Biosciences has a fifty-two week low of $0.76 and a fifty-two week high of $2.40. The company has a market capitalization of $7.27 million, a P/E ratio of -32.80 and a beta of 0.59. The stock has a fifty day moving average of $1.75 and a 200-day moving average of $1.71.

Interpace Biosciences (OTCMKTS:IDXG) last released its quarterly earnings results on Tuesday, May 12th. The business services provider reported $0.03 EPS for the quarter. Interpace Biosciences had a net margin of 65.25% and a return on equity of 219.07%. The business had revenue of $9.03 million for the quarter.

About Interpace Biosciences

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.